Silvr, since ATRS announced on June 7, 2017 that that they secured up to $35 million in debt financing to launch XYOSTED. FDA PDUFA date is October 20th, 2017 we know their meeting does not relate to the launch.
A merger with ATRS could explain why ANIP wrote off their male testosterone and cancelled their exclusive distribution and supply agreement with Aspen Global Incorporated for Hydroxyprogesterone Caproate Injection ("HPC") USP 250mg/mL in 5mL vials. HPC would compete directly with AMAG's Makena.
ATRS has Quickshot testosterone (Xyosted) and ATRS partners with AMAG on their new Makena auto injector where AMAG has filed a sNDA April 2017 (expects FDA review to be completed in 6 months)
Interestingly ATRS core business is auto injectors and gels. Art Przybl prior to being Akorn's CEO, he served as President and Chief Operating Officer of Bioject Inc, a company specializing in needle-free technology.
Add in Libigel and a merger just seems like a no brainer.
News 
Market Data 
Discover 
